The Rocky Road to Effective Treatment of Human Immunodeficiency Virus (HIV) Infection
Authors: Martin S. Hirsch
Journal: Annals of Internal Medicine (1989)

Editorials1 January 1989The Rocky Road to Effective Treatment of Human Immunodeficiency Virus (HIV) InfectionMartin S. Hirsch, MDMartin S. Hirsch, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-1-1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt has now been 7 years since the first clinical descriptions of the acquired immunodeficiency syndrome (AIDS), 4 years since HIV-1 was established as its cause, and 2 years since zidovudine (azidothymidine, Retrovir) was shown to improve survival from advanced HIV-1 infection (1). Moreover, intensive investigation into the replicative mechanisms of HIV-1 has led to a veritable flood of new agents that inhibit viral replication in vitro and will require further clinical investigation (2, 3). With this flood of information has come a tidal wave of rising public expectations that threatens the ability to conduct controlled clinical trials. An understanding...References1. FischlRichmanGrieco MDM. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-91. CrossrefMedlineGoogle Scholar2. VogtHirsch MM. Treatment of human immunodeficiency virus infection. Infectious Disease Clinics of North America. 1987;1:323-39. CrossrefMedlineGoogle Scholar3. YarchoanBroder RS. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. N Engl J Med. 1987;319:557-64. CrossrefGoogle Scholar4. Hirsch M. AIDS Commentary. Azidothymidine. J Infect Dis. 1988;157:427-31. CrossrefMedlineGoogle Scholar5. RichmanFischlGrieco DMM. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192-7. CrossrefMedlineGoogle Scholar6. Barry D. Improved long-term survival among patients with acquired immunodeficiency syndrome (AIDS) receiving Retrovir therapy. Retrovir satellite symposium. IV International Conference on AIDS, Stockholm, June 12, 1988. Google Scholar7. Creagh-KirkDoiAndrewsNusinoff-LehrmanTilsonHothBarry TPESHDD. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA. 1988;260:3009-15. CrossrefMedlineGoogle Scholar8. . Predictors of AZT tolerance. Proceedings of the IV International Conference on AIDS, Stockholm, June 12-16, 1988 (Abstract 3664). Google Scholar9. GillRarickBrynesCauseyLoureiroLevine PMRDCA. Azidothymidine associates with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med. 1987;107:502-5. LinkGoogle Scholar10. CohnShapiroKeyesSmothers JCCK. Neurologic disease associated with zidovudine. Proceedings of the 27th ICAAC, NY, October 4-7, 1987 (Abstract 381). Google Scholar11. SpearKesslerNusinoff Lehrmande Miranda JHSP. Zidovudine overdosage. Ann Intern Med. 1988;109:76-7. LinkGoogle Scholar12. YarchoanBergBrowers RGP. Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet. 1987;1:132-5. CrossrefMedlineGoogle Scholar13. PizzoEddyFalloon PJJ. Effects of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988;319:889-96. CrossrefMedlineGoogle Scholar14. HelbertRobinsonPeddle MDB. Acute meningo-encephalitis on dose reduction of zidovudine. Lancet. 1988;1:1249-52. CrossrefMedlineGoogle Scholar15. DovicRiosBrewton MAG. Remission of AIDS-associated psoriasis with zidovudine [Letter]. Lancet. 1987;2:627. CrossrefGoogle Scholar16. GottliebWolfeChafey MPS. Response of AIDS-related thrombocytopenia to intravenous and oral azidothymidine (3′-azi-do-3′-deoxythymidine). AIDS Res Human Retroviruses. 1987; 3:109-14. CrossrefMedlineGoogle Scholar17. . Zidovudine for the treatment of thrombocytopenia associated with human immunodeficiency virus (HIV) a prospective study. Ann Intern Med. 1988;109:718-21. LinkGoogle Scholar18. BalfourChinnockHenryFletcherde MirandaQuinn HBKCPR. Update on pharmacodynamic and virologic aspects of zidovudine. Retrovir satellite symposium, IV International Conference on AIDS. Stockholm, June 12, 1988. Google Scholar19. YarchoanPernoThomas RCR. Phase I studies of 2', 3'-dideoxycytidine in severe human immunodeficiency virus infections as a single agent and alternating with zidovudine (AZT). Lancet. 1988;1:76-81. CrossrefMedlineGoogle Scholar20. MeriganSkowronBozzette TGS. Circulating p-24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. Ann Intern Med. 1989;110[In press]. LinkGoogle Scholar21. VogtHartshornFurman MKP. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science. 1987;235:1376-9. CrossrefMedlineGoogle Scholar22. VogtDurnoChou MAT. Synergistic interaction of 2', 3'-dideoxycytidine and recombinant interferon alpha-A on replication of human immunodeficiency virus type 1. J Infect Dis. 1988;158:378-85. CrossrefMedlineGoogle Scholar23. Seligmann M. Zidovudine, plus or minus acyclovir, in the treatment of AIDS patients post-opportunistic infection. Retrovir satellite symposium, IV International Conference on AIDS, Stockholm, June 12, 1988. Google Scholar24. ZamecnikGoodchildTaguchiSarin PJYP. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sci USA. 1986;83:4143-6. CrossrefMedlineGoogle Scholar25. WalkerKowalskiGoh BMW. Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc Natl Acad Sci USA. 1987;84:8120-4. CrossrefMedlineGoogle Scholar26. PauewelsBalzariniSchols RJD. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother. 1988;32:1025-30. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Massachusetts General Hospital Harvard Medical School Boston, Massachusetts Nextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCelebrating the ACP Centennial: From the Annals Archive—HIV Research and Therapies Deputy Editor Deborah Cotton Metrics Cited byCelebrating the ACP Centennial: From the Annals Archive—HIV Research and TherapiesDeborah Cotton, MD, MPHLow-dose zalcitabine-related toxic neuropathy: Frequency, natural history, and risk factors.Effect of Daily Zidovudine (AZT) Pulse-Therapy on Replication of Human Immunodeficiency Virus Type 1 and Type 2 in vitroAIDS in Uganda — Clinical and Social FeaturesGenitourinary Medicine and Sexually Transmitted Diseases in the 1990sHuman Immunodeficiency Virus InfectionPROBENECID AND ZIDOVUDINE METABOLISMTreatment dilemmas for HIV infected haemophiliacs 1 January 1989Volume 110, Issue 1Page: 1-3KeywordsAIDSAzidothymidineClinical trialsHIVHIV infectionsHIV-1Infectious diseasesMotivationViral replication ePublished: 1 December 2008 Issue Published: 1 January 1989 PDF downloadLoading ...